Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:BISNASDAQ:FTXHNASDAQ:JDOCNASDAQ:MEDX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBISProShares UltraShort Nasdaq Biotechnology$21.02+3.6%$19.10$14.05▼$25.87$3.57M-1.4111,313 shs4,047 shsFTXHFirst Trust Nasdaq Pharmaceuticals ETF$24.52-1.8%$26.10$23.29▼$29.72$13.49M0.75,822 shs278,485 shsJDOCJPMorgan Healthcare Leaders ETF$49.17-0.5%$51.59$48.54▼$63.49$7.38M0.61410 shs207 shsMEDXHorizon Kinetics Medical ETF$25.15-1.0%$26.62$23.46▼$32.00$14.84M0.911,101 shs224 shs13 Stocks Institutional Investors Won't Stop BuyingWhich stocks are hedge funds and endowments buying in today's market? Enter your email address and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying now.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBISProShares UltraShort Nasdaq Biotechnology+3.88%+17.82%-1.18%+25.57%+15.62%FTXHFirst Trust Nasdaq Pharmaceuticals ETF-1.80%-4.87%-1.29%-10.46%-8.37%JDOCJPMorgan Healthcare Leaders ETF-2.21%-3.30%+1.30%-9.88%-13.60%MEDXHorizon Kinetics Medical ETF-1.17%-6.61%+1.09%-9.11%-11.69%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationBISProShares UltraShort Nasdaq BiotechnologyN/AN/AN/AN/AN/AN/AN/AN/AFTXHFirst Trust Nasdaq Pharmaceuticals ETFN/AN/AN/AN/AN/AN/AN/AN/AJDOCJPMorgan Healthcare Leaders ETFN/AN/AN/AN/AN/AN/AN/AN/AMEDXHorizon Kinetics Medical ETFN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBISProShares UltraShort Nasdaq Biotechnology 0.00N/AN/AN/AFTXHFirst Trust Nasdaq Pharmaceuticals ETF 2.60Moderate Buy$24.52N/AJDOCJPMorgan Healthcare Leaders ETF 2.75Moderate Buy$49.17N/AMEDXHorizon Kinetics Medical ETF 2.68Moderate Buy$25.15N/ACurrent Analyst Ratings BreakdownCompare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBISProShares UltraShort Nasdaq BiotechnologyN/AN/AN/AN/AN/AN/AFTXHFirst Trust Nasdaq Pharmaceuticals ETFN/AN/AN/AN/AN/AN/AJDOCJPMorgan Healthcare Leaders ETFN/AN/AN/AN/AN/AN/AMEDXHorizon Kinetics Medical ETFN/AN/AN/AN/AN/AN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBISProShares UltraShort Nasdaq BiotechnologyN/AN/A0.00∞N/AN/AN/AN/AN/AFTXHFirst Trust Nasdaq Pharmaceuticals ETFN/AN/A17.67∞N/AN/AN/AN/AN/AJDOCJPMorgan Healthcare Leaders ETFN/AN/A30.21∞N/AN/AN/AN/AN/AMEDXHorizon Kinetics Medical ETFN/AN/A26.54∞N/AN/AN/AN/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthBISProShares UltraShort Nasdaq Biotechnology$0.653.09%N/AN/AN/AFTXHFirst Trust Nasdaq Pharmaceuticals ETF$0.481.96%N/AN/AN/AJDOCJPMorgan Healthcare Leaders ETF$2.815.71%N/AN/AN/AMEDXHorizon Kinetics Medical ETF$0.501.99%N/AN/AN/ALatest FTXH, MEDX, JDOC, and BIS DividendsAnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date3/25/2025BISProShares UltraShort Nasdaq BiotechnologyQuarterly$0.13252.99%3/26/20253/26/20254/1/20253/26/2025FTXHFirst Trust Nasdaq Pharmaceuticals ETFQuarterly$0.09921.45%3/27/20253/27/20253/31/2025(Data available from 1/1/2013 forward)Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBISProShares UltraShort Nasdaq BiotechnologyN/AFTXHFirst Trust Nasdaq Pharmaceuticals ETFN/AJDOCJPMorgan Healthcare Leaders ETFN/AMEDXHorizon Kinetics Medical ETF62.18%Insider OwnershipCompanyInsider OwnershipBISProShares UltraShort Nasdaq BiotechnologyN/AFTXHFirst Trust Nasdaq Pharmaceuticals ETFN/AJDOCJPMorgan Healthcare Leaders ETFN/AMEDXHorizon Kinetics Medical ETF4.30%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBISProShares UltraShort Nasdaq BiotechnologyN/A170,000N/AOptionableFTXHFirst Trust Nasdaq Pharmaceuticals ETF147,000550,000N/AOptionableJDOCJPMorgan Healthcare Leaders ETFN/A150,000N/AN/AMEDXHorizon Kinetics Medical ETFN/A590,000N/ANot OptionableFTXH, MEDX, JDOC, and BIS HeadlinesRecent News About These CompaniesHorizon Kinetics Holding Corporation Reports Fourth Quarter and Annual ResultsMarch 26, 2025 | accessnewswire.comETFs to Buy as Eli Lilly Beats Q1 Earnings, Lifts OutlookMay 1, 2024 | zacks.comHorizon Kinetics ISE Wealth (RCH)May 13, 2023 | uk.investing.comHORIZON Fushi ChinaA 50 ETF (512150)May 11, 2023 | investing.comHorizon Kinetics Launches the Horizon Kinetics SPAC Active ETF (SPAQ) and the Horizon Kinetics Medical ETF (MEDX)April 19, 2023 | finance.yahoo.comMedia Sentiment Over TimeFTXH, MEDX, JDOC, and BIS Company DescriptionsProShares UltraShort Nasdaq Biotechnology NASDAQ:BIS$21.02 +0.74 (+3.65%) As of 05/9/2025 04:00 PM EasternProShares Ultra Nasdaq Biotechnology (the Fund) seeks investment results for a single day only, not for longer periods. The Fund seeks daily investment results, before fees and expenses, that correspond to twice (200%) the daily performance of the Index. The return of the Fund for a period longer than a single trading day will be the result of each day's returns compounded over the period, which will very likely differ from twice (200%) the return of the Nasdaq Biotechnology Index (the Index) for that period. The Fund does not seek to achieve its stated investment objective over a period of time greater than one day. The Fund invests in equity securities and derivatives that have similar daily performance characteristics as twice (200%) the daily return of the Index. The Fund invests in financial instruments whose value is derived from the value of an underlying asset, interest rate or index. ProShare Advisors LLC is the investment advisor of the Fund.First Trust Nasdaq Pharmaceuticals ETF NASDAQ:FTXH$24.52 -0.45 (-1.80%) As of 05/9/2025 02:45 PM EasternThe First Trust Nasdaq Pharmaceuticals ETF (FTXH) is an exchange-traded fund that is based on the Nasdaq US Smart Pharmaceuticals index. The fund tracks the 30 most liquid US pharmaceutical companies, weighted according to factors related to value, volatility, and growth. FTXH was launched on Sep 20, 2016 and is managed by First Trust.JPMorgan Healthcare Leaders ETF NASDAQ:JDOC$49.17 -0.26 (-0.53%) As of 05/9/2025 10:40 AM EasternThe JPMorgan Healthcare Leaders ETF Healthcare Leaders ETF (JDOC) is an exchange-traded fund that mostly invests in health care equity. The fund is actively managed, investing in equity securities issued by pharmaceutical, biotechnology, healthcare services, healthcare technology, medical technology and life sciences companies located around the globe.The adviser seeks to provide long-term capital appreciation. JDOC was launched on Nov 1, 2023 and is issued by JPMorgan Chase.Horizon Kinetics Medical ETF NASDAQ:MEDX$25.15 -0.26 (-1.02%) As of 05/9/2025 12:51 PM EasternThe Horizon Kinetics Medical ETF (MEDX) is an exchange-traded fund that mostly invests in health care equity. The fund actively invests in global companies within the broad health care sector. Stock selection and weighting emphasizes those invested in cancer research and pharmaceutical developments. MEDX was launched on Jan 27, 2023 and is managed by Horizon Kinetics. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 05/05 - 05/09 Taiwan Semiconductor Has a New Reason to Rally on Chip Curbs Why Nearly 20 Analysts Raised Meta Price Targets Post-Earnings Strategists Say Hold: Stocks May Beat the 'Sell in May' Trend Here's The Reason Goldman Sachs Is Bullish On MercadoLibre Stock GlobalFoundries Stock Hits Bottom: Is a Rebound Coming? What the ExtraHop Deal Means for CrowdStrike DoorDash’s Uptrend Is Gaining Momentum in 2025 Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
